1 ADHD drugs and CV outcomes: Preliminary feasibility results and potential observational studies David J. Graham, MD, MPH on behalf of the FDA Epidemiology.

Slides:

Advertisements

Similar presentations

National Health Policy Conference, Washington, DC February 6, Drug Safety Challenges: Considerations for Sources of Data Gerald J. Dal Pan, MD,

Advertisements

Agency for Healthcare Research and Quality (AHRQ)

Population Trends in the Incidence and Outcomes of Acute Myocardial Infarction Robert W. Yeh, MD MSc Massachusetts General Hospital Alan S. Go, MD Kaiser.

Sumeet Subherwal, Richard G. Bach, Anita Y. Chen, Brian F. Gage, Sunil V. Rao, Tracy Y. Wang, W. Brian Gibler, E. Magnus Ohman, Matthew T. Roe, Eric D.

Department of Health and Human Services Center for Drug Evaluation and Research Review of Epidemiologic Studies on Cardiovascular Risk with Selected NSAIDs.

STD Screening in HIV Clinics: Value and Implications Thomas Farley, MD MPH Tulane University Deborah Cohen, MD MPH RAND Corporation.

Principles of case control studies Part I Nature of the design of case control studies Odds ratio as the measurement of association Piyanit Tharmaphornpilas.

Sensitivity Analysis for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)

Primary care of hypertensive patients and the risk of acute events Irina Stirbu-Wagner Markus MJ Nielen Maaike Langelaan Robert A. Verheij Joke C. Korevaar.

A-1 Pravastatin-Aspirin Introduction Todd Baumgartner, MD, MPH Vice President Regulatory Sciences Pharmaceutical Research Institute Bristol-Myers Squibb.

Intermediate methods in observational epidemiology 2008 Instructor: Moyses Szklo Measures of Disease Frequency.

Measures of association

RACIAL DISPARITIES IN PRESCRIPTION DRUG UTILIZATION AN ANALYSIS OF BETA-BLOCKER AND STATIN USE FOLLOWING HOSPITALIZATION FOR ACUTE MYOCARDIAL INFARCTION.

Main Points to be Covered Cumulative incidence using life table method Difference between cumulative incidence based on proportion of persons at risk and.

Measuring Epidemiologic Outcomes

Successful Approaches to Reduce Hypertension Stephen Sidney, MD, MPH Kaiser Permanente Northern California October 17, 2012.

Incidence and Prevalence

Population Impact Measures (PIM)

An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,

Multiple Choice Questions for discussion

Evidence-Based Medicine 4 More Knowledge and Skills for Critical Reading Karen E. Schetzina, MD, MPH.

Complete Recovery of Renal Function After Acute Kidney Injury is Associated with Long-Term All-Cause Mortality In a Large Managed Care Organization Jennifer.

In Hospital Hip Fracture Mortality Colleen McLaughlin, MPH, PhD Division of Quality and Patient Safety.

Overview of Issues for Psychopharmacological Drugs Advisory Committee June 16, 2003 WBC Monitoring for Clozapine Judith A. Racoosin, MD, MPH Safety Team.

1 Improving Chronic Care Management David M. Cutler Presented at Alliance for Health Reform Novartis/NIHCM Briefing March 28, 2008.

‘STROKE’ February 2011 Dr Amer Jafar ABHB/Gwent. Decreased Kidney Function  Chronic kidney disease is an important risk factor for development and progression.

March 31, 2006FDA Science Board1 CDER's Office of Drug Safety: Electronic Tools for Risk Assessment and Evaluation Paul J. Seligman, M.D., M.P.H. Director.

An epidemiologic perspective on etoricoxib David J. Graham, MD, MPH Office of Surveillance and Epidemiology April 12, 2007.

Farrokh Alemi, Ph.D..  Compare effectiveness  Low dose rofecoxib (Vioxx)  High dose rofecoxib (Vioxx)  Celecoxib  Other medication.

Population-Based Epidemiologic Safety Studies: Overview and Challenges Drug Safety and Risk Management Advisory Committee Silver Spring, Maryland June.

Measuring the Occurrence of Disease 1 Sue Lindsay, Ph.D., MSW, MPH Division of Epidemiology and Biostatistics Institute for Public Health San Diego State.

Center for Drug Evaluation and Research Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management.

1 Lotronex Postmarketing Experience Ann Corken Mackey, R.Ph., M.P.H. Allen Brinker, M.D., M.S. Zili Li, M.D., M.P.H., formerly of ODS Office of Drug Safety.

VIOXX ™ Gastrointestinal Outcome Research (VIGOR) Arthritis Advisory Committee Meeting February 8, 2001 Lourdes Villalba, M.D. DAAODP, CDER, FDA.

RATES AND RISK Daniel E. Ford, MD, MPH Johns Hopkins School of Medicine Introduction to Clinical Research July 12, 2010.

Drug Safety and Risk Management Advisory Committee May 18-19, Overview of Drug Safety Challenges Gerald J. Dal Pan, MD, MHS Director Division of.

LEADING RESEARCH… MEASURES THAT COUNT Challenges of Studying Cardiovascular Outcomes in ADHD Elizabeth B. Andrews, MPH, PhD, VP, Pharmacoepidemiology and.

Sudden Death in Young Adults: An Autopsy Based Series on a Population Undergoing Active Surveillance Robert E. Eckart, DO, FACC, Eric A. Shry, MD, FACC,

The National Electronic Injury Surveillance System: Cooperative Adverse Drug Events Surveillance System (NEISS-CADES) Aaron B. Mendelsohn, PhD, MPH Office.

Describing the risk of an event and identifying risk factors Caroline Sabin Professor of Medical Statistics and Epidemiology, Research Department of Infection.

A Claims Database Approach to Evaluating Cardiovascular Safety of ADHD Medications A. J. Allen, M.D., Ph.D. Child Psychiatrist, Pharmacologist Global Medical.

1 Statistical Review of the Observational Studies of Aprotinin Safety Part II: The i3 Drug Safety Study CRDAC and DSaRM Meeting September 12, 2007 P. Chris.

Effect of Rosiglitazone on the Risk of Myocardial Infarction And Death from Cardiovascular Causes Alternative Interpretations of the Evidence George A.

BIOSTATISTICS Lecture 2. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and creating methods.

1 Risk Intervention Study: Cisapride Evelyn M Rodriguez MD, MPH Director, DDREII, OPDRA.

Health Care Market Structure, Safety Net Hospitals, and the Quality of Hospital Care José J. Escarce, MD, PhD David Geffen School of Medicine at UCLA and.

Case-Control Studies September 2014 Alexander M. Walker MD, DrPH With Sonia Hernández-Díaz MD, DrPH.

Nurse Staffing and Quality of Care for Hospitalized Children Barbara A. Mark Ph.D., R.N. FAAN University of North Carolina at Chapel Hill David W. Harless.

Question 1 Please identify and discuss the most important outcomes to study in both children and adults. Please consider: –Whether the choice of outcomes.

以多重死因資料比較台灣美國腦中風併發吸入性肺炎之趨勢奇美醫學中心張嘉祐醫師. Stroke Statistics -- A Report From the American Heart Association Approximately 56% of stroke deaths in 2009.

Uses of the NIH Collaboratory Distributed Research Network Jeffrey Brown, PhD for the DRN Team Harvard Pilgrim Health Care Institute and Harvard Medical.

EPI 5344: Survival Analysis in Epidemiology Week 6 Dr. N. Birkett, School of Epidemiology, Public Health & Preventive Medicine, University of Ottawa 03/2016.

1 Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee February 2, 2004 Office of Drug.

Viagra (sildenafil citrate): Extensive Clinical and Post-Marketing Experience Michael Sweeney, MD Senior Medical Director Pfizer Inc.

CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.

ADHD drugs and CV outcomes: Preliminary feasibility study results David J. Graham, MD, MPH on behalf of the FDA Epidemiology Contracts Study Team DSARM.

Research Activities at The Boston Collaborative Drug Surveillance Program; Boston University School of Public Health Susan Jick Professor of Epidemiology.

Instructional Objectives:

Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study Kirchgesner J, et al. Gut 2017;0:1–8.

Update on the Watchman Device CRT 2010 Washington, DC

Epidemiologic Measures of Association

Improving Chronic Care Management

Cardiovascular Disease (CVD) in Texas

Trends in Stroke Rates, Risk, and Outcomes in the United States, 1988 to 2008 Margaret C. Fang, MD, MPH, Marcelo Coca Perraillon, MA, Kaushik Ghosh, PhD,

George Washington University

The US Renal Data System “Pie Chart of Death”

Global collaborative research through OHDSI network: Febuxostat vs Allopurinol Seng Chan You MD; Ju-Yang Jung, MD; Chang-Hee Su, MD, PhD; Rae Woong Park,

Statement on Concerta and Methylphenidate for the June 30, 2005 Pediatric Advisory Committee The FDA has identified two possible safety concerns with.

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

Presentation transcript:

1 ADHD drugs and CV outcomes: Preliminary feasibility results and potential observational studies David J. Graham, MD, MPH on behalf of the FDA Epidemiology Contracts Study Team March 22, 2006

2 FDA’s Epidemiology Contracts Program Replaces Cooperative Agreement Program Provides capability to study safety questions in a population setting 4 awardees Covered lives HMO Research Network 3.2 million Ingenix (i3 Drug Safety) 12 million Kaiser Permanente Research Institute 6.1 million TN and WA Medicaid 2.2 million Turnover: 1 yr: 8%-30%; 5 yrs: 25%-80% Funding $1.6 million $0.9 million

3 Feasibility study design Inception cohorts, all ages Study period Jan 1998-June 2005 (i3, KPRI, Medicaid) July 2000-June 2005 (HMO RN) Drugs of interest Amphetamine or dextroamphetamine Methylphenidate Atomoxetine Age-groups Children/adolescents (1-19 years) Adults (20-64 years) Outcomes of interest Sudden unexplained death Acute myocardial infarction Other ischemic heart disease Cerebrovascular accident Arrhythmia Hypertension Pulmonary hypertension

4 Details of ADHD drug exposure cohorts of children ≤ 19 years

5 Persistency of ADHD drug use by drug in 0-19 year olds Methylphenidate  Amphetamine  Atomoxetine 

6 Background rates for cardiovascular events of interest in pediatric population age 1-19

7 Counts of potential study outcomes in children age 1-19 years, based on hospital discharge diagnoses

8 Deaths reported within pediatric ADHD-drug- exposed inception cohorts Deaths occurred at any time after cohort entry From any cause In-hospital only from 2 sites, none from 1 site Sudden out of hospital deaths included from 1 site 2 sites have death certificate linkage; SCD validated at 1 NDI search required with other 2 sites - turnover, time, $$

9 Power to identify a given risk ratio with a background rate = 15 per 10 5 person-years (AMI in children 1-19 years) Power (1-beta) Exposure cohort person-years (thousands ) RR=2 RR=3 RR=5

10 Power to identify a given risk ratio with a background rate = 3 per 10 5 person-years (CVA in children 1-19 years) Power (1-beta) Exposure cohort person-years (thousands) RR=2 RR=3 RR=5 RR=10

11 RR=2 RR=3 RR=5 RR=10 Event number and statistical power required to confirm risk ratios from 2 to 10

12 Probability of excluding a given risk ratio, assuming true RR=1: background = 15 per 10 5 person-years (AMI in children age 1-19) RR=2 RR=3 RR=5

13 Probability of excluding a given risk ratio, assuming true RR=1: background = 3 per 10 5 person-years (CVA in children age 1-19) RR=10 RR=5 RR=3 RR=2

14 Estimated risk ratio that can be detected with  80% probability by age- and drug-group

15 Some additional power considerations AMI: acute myocardial infarction CVA: cerebrovascular accident (stroke)

16 Caveats regarding ADHD cohort study Preliminary data; relationship of drug exposures to outcomes not yet studied Crude definitions of exposure, outcome Hospital D/C diagnoses, not validated Outcome post 1st Rx; timing with current use not known Out of hospital deaths (SCD) not captured at 2 sites Power calculations crude Uncertainty regarding background rates (i.e., AMI)

17 Proposal offered at February advisory meeting Observational echocardiographic study Within a large healthcare database: Identify patients treated with ADHD drugs for varying durations of time Select suitable untreated “controls” from same population Perform echocardiography and assess Left ventricular wall thickness Contractility

18 Patient sampling for echocardiographic study Methylphenidate  Amphetamine  Atomoxetine 

19 Summary Concern regarding potential for CV risk of ADHD drugs High prevalence of use in children; growing in adults Sudden unexplained death of 1  interest; most difficult to study TN Medicaid and KPRI have death certificate linkage Other sites would require NDI search Other CV outcomes Feasibility study Exposed person-time substantial for most ADHD drugs CV outcomes require validation; timing with respect to exposure Statistical power and uncertainty Number of arrhythmia cases seems surprisingly high Now in process of obtaining cost estimates for in-depth study

20 FDA Epidemiology Contracts ADHD Study Team (list by site) FDA, ODS Andrew Mosholder, MD, MPH Kate Gelperin, MD, MPH Judy A. Staffa, PhD David J. Graham, MD, MPH HMO Research Network Susan E. Andrade, PhD Ingenix (i3 Drug Safety) K. Arnold Chan, MD, ScD Kaiser Permanente Research Institute Joe Selby, MD, MPH Medicaid (TN and WA) William Cooper, MD, MPH